Literature DB >> 31145644

Mapping of local recurrence after pancreaticoduodenectomy for distal extrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy.

Wonguen Jung1, Kyubo Kim1, Seog Ki Min2, Eun Mi Nam3, Jeong Kyong Lee4.   

Abstract

OBJECTIVE: To generate a map of local recurrences after pancreaticoduodenectomy (PD) for patients with distal extrahepatic cholangiocarcinoma (DEHC) and to evaluate the adequate target volume coverage encompassing the majority of local recurrences when the clinical target volume (CTV) for pancreatic cancer was applied.
METHODS: We retrospectively reviewed the records of DEHC patients who underwent pancreaticoduodenectomy and had postoperative CT scans acquired between 1991 and 2015 available. The sites of local recurrence were delineated on individual CT scans, and then, mapping was manually performed onto template CT images. Coverage of each site of local recurrence was evaluated by applying the CTV defined according to Radiation Therapy Oncology Group (RTOG) consensus guidelines (CTVRTOG ) for target delineation in the postoperative treatment of pancreatic head cancer.
RESULTS: Of the 99 patients, 36 patients had a total of 62 local relapses identifiable by postoperative CT scans; the relapses were the most frequent in the choledochojejunostomy (CJ) site, 11 sites (17.7%); para-aortic area, 10 sites (16.1%), superior mesenteric artery area, 10 sites (16.1%); and portal vein area, 9 sites (14.5%). 21 sites (33.9%) were not covered by the CTVRTOG, and the most common site of local recurrence outside the CTVRTOG was the CJ site.
CONCLUSION: When mapping of local relapses was evaluated according to the CTVRTOG, the choledochojejunostomy site was identified as a high-risk area of local recurrence but was insufficiently covered within the CTVRTOG. These findings may help construct a target volume for postoperative radiotherapy in DEHC. ADVANCES IN KNOWLEDGE: Mapping local recurrences can aid in defining appropriate target volume for postoperative radiotherapy in DEHC.

Entities:  

Mesh:

Year:  2019        PMID: 31145644      PMCID: PMC6724627          DOI: 10.1259/bjr.20190285

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  26 in total

1.  Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis.

Authors:  Tamara Z Vern-Gross; Anand T Shivnani; Ke Chen; Christopher M Lee; Jonathan D Tward; O Kenneth MacDonald; Christopher H Crane; Mark S Talamonti; Louis L Munoz; William Small
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-23       Impact factor: 7.038

2.  Nodal areas of potential geographic error in adjuvant radiotherapy for biliary tract cancer.

Authors:  Joanna Socha; Maciej Michalak; Grzegorz Wołąkiewicz; Lucyna Kepka
Journal:  Radiother Oncol       Date:  2017-10-13       Impact factor: 6.280

3.  Prognostic significance of lymph node involvement in middle and distal bile duct cancer.

Authors:  R Sasaki; M Takahashi; O Funato; H Nitta; M Murakami; H Kawamura; T Suto; S Kanno; K Saito
Journal:  Surgery       Date:  2001-06       Impact factor: 3.982

4.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

5.  The pattern of lymphatic spread in carcinoma of the distal bile duct.

Authors:  T Yoshida; M Aramaki; T Matsumoto; Y Morii; A Sasaki; S Kitano
Journal:  Int Surg       Date:  1998 Apr-Jun

6.  Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design.

Authors:  Avani S Dholakia; Rachit Kumar; Siva P Raman; Joseph A Moore; Susannah Ellsworth; Todd McNutt; Daniel A Laheru; Elizabeth Jaffee; John L Cameron; Phuoc T Tran; Robert F Hobbs; Christopher L Wolfgang; Joseph M Herman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-12-01       Impact factor: 7.038

7.  Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer.

Authors:  M Kayahara; T Nagakawa; T Ohta; H Kitagawa; H Tajima; K Miwa
Journal:  Ann Surg       Date:  1999-01       Impact factor: 12.969

8.  Adjuvant radio-chemotherapy for extrahepatic biliary tract cancers.

Authors:  Marta Bonet Beltrán; Arnaud D Roth; Gilles Mentha; Abdelkarim S Allal
Journal:  BMC Cancer       Date:  2011-06-24       Impact factor: 4.430

9.  An atlas for clinical target volume definition, including elective nodal irradiation in definitive radiotherapy of biliary cancer.

Authors:  Silvia Bisello; Matteo Renzulli; Milly Buwenge; Lucia Calculli; Giuseppina Sallustio; Gabriella Macchia; Francesco Deodato; Giancarlo Mattiucci; Silvia Cammelli; Alessandra Arcelli; Lucia Giaccherini; Francesco Cellini; Giovanni Brandi; Sara Guerri; Savino Cilla; Rita Golfieri; Lorenzo Fuccio; Alessio G Morganti; Alessandra Guido
Journal:  Oncol Lett       Date:  2018-11-28       Impact factor: 2.967

Review 10.  Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity.

Authors:  Rosa B Schmuck; Cynthia V de Carvalho-Fischer; Christopher Neumann; Johann Pratschke; Marcus Bahra
Journal:  Cancer Med       Date:  2015-12-09       Impact factor: 4.452

View more
  2 in total

1.  Adjuvant Radiotherapy for Extrahepatic Cholangiocarcinoma: A Quality Assessment-Based Meta-Analysis.

Authors:  Seo Hee Choi; Chai Hong Rim; In-Soo Shin; Won Sup Yoon; Woong Sub Koom; Jinsil Seong
Journal:  Liver Cancer       Date:  2021-08-26       Impact factor: 11.740

2.  Variation in clinical target volume delineation in postoperative radiotherapy for biliary tract cancer.

Authors:  Taeryool Koo; Kwang-Ho Cheong; Kyubo Kim; Hae Jin Park; Younghee Park; Hyeon Kang Koh; Byoung Hyuck Kim; Eunji Kim; Kyung Su Kim; Jin Hwa Choi
Journal:  PLoS One       Date:  2022-09-01       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.